AbbVie entered December 30, 2025, following a strong year, buoyed by positive analyst sentiment in December with upgrades from HSBC and Morgan Stanley raising price targets. The company also progressed its pipeline, marking primary completion dates for multiple Q4 2025 clinical trials, including those for Botox and Epcoritamab. However, market sentiment remains attentive to the unresolved MFN drug pricing policy, as AbbVie was not part of the December 19 agreements, implying continued policy risk.